Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
AIDS and HIV
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - AIDS and HIV
    ACP Recommends HIV Screening for All Patients, Regardless of Risk Factors - (DGNews)
    FDA Grants Full Approval of Maraviroc for Treatment-Experienced Patients With HIV - (DGNews)
    TopAbstracts in AIDS and HIV 11/24/2008 - (DGNews)
    Early Antiretroviral Therapy and Mortality among HIV-Infected Infants - (N Engl J Med)
    Percutaneous Coronary Intervention Safe in Patients Infected With HIV: Presented at AHA - (DGDispatch)

    News archive

     Recent webcasts/CME - AIDS and HIV

    Webcasts/CME archive

     Recent cases - AIDS and HIV
      Soft Tissue Non-Hodgkin Lymphoma of Shoulder in a HIV Patient: A Report of a Case and Review of the Literature
      HIV, Visceral Leishmaniasis and Parkinsonism Combined with Diabetes Mellitus and Hyperuricaemia: A Case Report
      Primary Kaposi Sarcoma of the Subcutaneous Tissue
      Primary Malignant Melanoma of the Esophagus With Separate Foci of Melanoma In Situ and Atypical Melanocytic Hyperplasia in a Patient Positive for Human Immunodeficiency Virus: A Case Report and Review of the Literature
      HIV-2 Diagnosis and Quantification in High-Risk Patients

      Cases archive
        




      my personal edition > aids and hiv > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Early Results Show Efficacy With Gilead Integrase Inhibitor: Presented at CROI

      By Ed Susman

      DENVER, CO -- February 9, 2006 -- In a phase 1/2, 10-day monotherapy trial, the integrase inhibitor GS9317 was able to lower HIV viral loads by as much as 2 logs -- 99%.

      Researchers used 5 different GS9317 dosing regimens in the trial -- 200 mg twice a day, 400 mg twice a day, 800 mg twice a day, 800 mg once a day, or 50 mg boosted by 100 mg ritonavir once a day.

      "In all cases, GS9137 outperformed the placebo arm of the trial," said Andrew Cheng, MD, vice president for clinical research, Gilead Sciences, Forster City, California. Dr. Cheng presented the study findings here on February 8th at the 13th Conference on Retroviruses and Opportunistic Infections (CROI).

      He noted, however, that ritonavir allows GS9137 to remain in the bloodstream up to 9 hours.

      The study evaluated the antiviral activity, safety, and pharmacokinetic properties for the integrase inhibitor, Dr. Cheng said.

      Future studies of GS9137 will include ritonavir boosting, he said. Those trials will test 20 mg, 50 mg, and 125 mg, all of which will be boosted by ritonavir, Dr. Cheng said. The goal is to seek once-daily dosing of the drug, he added.

      In the 10-day monotherapy trials, Dr. Cheng said that GS9137 reduced circulating HIV in the blood by as much as 2log10. He tested 30 patients with the various dosages and compared them with 10 patients who were on placebo. The difference reached statistical significance at the P < .0001 level, he said.

      "The drug was also very well tolerated," Dr. Chang said. "All adverse events related to the study drug were grade 1 or grade 3 in severity, resolved on treatment, and were not associated with GS9137."

      He said that none of the patients in the study were forced to discontinue the study drug. There were no serious adverse events in the treatment arm, he said.


      [Presentation title: The HIV Integrase Inhibitor GS-9137 (JTK-303) Exhibits Potent Antiviral Activity in Treatment-Naïve and Experienced Patients. Abstract 160LB]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send